Skip to main content
SpringerLink
Log in

A Review of Clinical Trials Assessing the Efficacy and Safety of Newer Antiarrhythmic Drugs in Atrial Fibrillation

  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

Clinical trials assessing the efficacy of anti- arrhythmic drugs for terminating atrial fibrillation have demonstrated that rate control drugs have little to no added efficacy compared to placebo; however, spontaneous conversion of recent-onset atrial fibrillation is common. Antiarrhythmic drugs such as oral dofetilide, oral bolus-flecainide and propafenone and intravenous ibutilide all have a role in terminating atrial fibrillation. Active comparator trials have demonstrated that amiodarone is more efficacious in maintaining sinus rhythm than propafenone and sotalol. Multiple trials have demonstrated the safety of amiodarone, sotalol, dofetilide and azimilide in a post-myocardial infarction population and amiodarone and dofetilide in a congestive heart failure population. Newer antiarrhythmic agents, some with novel mechanisms of action, will add to the pharmacologic armamentarium in treating atrial fibrillation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Castro A, Bianconi L, Santini M. New antiarrhythmic drugs for the treatment of atrial fibrillation. PACE 2002;25:249–259.

    Google Scholar 

  2. Farshi R, Kistner D, Sarma JSM, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study if five drug regimens. J Am Coll Cardiol 1999;33:304–310.

    Google Scholar 

  3. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Intern Med 1987;106:503–506.

    Google Scholar 

  4. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group Investigators. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J 1997;18:649–654.

    Google Scholar 

  5. Dell'Orfano JT, Patel H, Wolbrette DL, Luck JC, Naccarelli GV. Acute treatment of atrial fibrillation: Spontaneous conversion rates and cost of care. Am J Cardiol 1999;83:788–790.

    Google Scholar 

  6. Danias PG, Caulfield TA, Weigner MJ, Silverman DI, Manning WJ. Likelihood of spontaneous conversion of atrial fibrilaltion to sinus rhythm. J AmColl Cardiol 1998;313:588–592.

    Google Scholar 

  7. Dell'Orfano JT, Blaha C, Kramer K, Patel H, Luck JC, Wolbrette DL, Naccarelli GV. A prospective evaluation of patients with acute atrial fibrillation: Using a clinical pathway improves length of stay and reduces cost of care (abstract). PACE 2000;23:668.

    Google Scholar 

  8. Naccarelli GV, Dell'Orfano JT, Wolbrette DL, Patel H, Luck JC. Acute cost-effective management of atrial fibrillation: Role of rate control, spontaneous conversion, cardioversion, and antiembolic therapy. Am J Cardiol 2000;85:36D–45D.

    Google Scholar 

  9. Fuster V, Rydé LE, Asinger RW, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for ractice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2001;38:1231–1265.

    Google Scholar 

  10. Halinen MO, Huttunen M, Paakkinen S, Tarssanen L. Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). Am J Cardiol 1995;76:495–498.

    Google Scholar 

  11. Capucci A, Villani GQ, Aschieri D, Piepoli M. Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm:Aprospective parallel placebocontrolled multicentre study. Int J Cardiol 1999;68:187–196.

    Google Scholar 

  12. Boriani G, Biffi M, Capucci A, Botto GL, Broffoni T, Rubino I, DellaCasa S, Sanguinetti M, Magnani B. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. Ann Intern Med 1997;126:621–625.

    Google Scholar 

  13. Volgman AS, Carberry PA, Stambler B, Lewis WR, Dunn GH, Perry KT, Vanderlugt JT, Kowey PR. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998;31:1414–1419.

    Google Scholar 

  14. Galve E, Rius T, Ballester R, Artaza MA, Arnau JM, Garcia-Dorado D, Soler-Soler J. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol 1996;27:1079–1082.

    Google Scholar 

  15. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or flutter: The Efficacy and Safety of Newer Antiarrhythmic Drugs in Atrial Fibrillation 221 symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000;102:2385–2390.

    Google Scholar 

  16. Greenbaum R, Campbell TJ, Channer KS, et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD study (abstract). Circulation 1998;I-633.

  17. Mounsey JP, DiMarco JP. Dofetilide. Circulation 2000;102:2665–2770.

    Google Scholar 

  18. Torp-Pedersen C, Moller M, Bloch-Thomsen PF, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999;341:857–865.

    Google Scholar 

  19. Zehender M, Hohnloser S, Muller B, Meinertz T, Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: Results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992;19:1054–1059.

    Google Scholar 

  20. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932–1939.

    Google Scholar 

  21. Naccarelli GV, Dorian P, Hohnsloser SH, Coumel P for the Flecainide Multicenter Atrial Fibrillation Study Group. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation. Am J Cardiol 1996;77:53A–59A.

    Google Scholar 

  22. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. AmJ Cardiol 1993;71:558–563.

    Google Scholar 

  23. Kochiadakis GE, Igoumenidis NE, Marketou ME, Solomou MC, Kanoupakis EM, Vardas PE. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1998;81:995–998.

    Google Scholar 

  24. Roy D, Talajic M, Dorian P, et al. for the Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Eng J Med 2000;342:913–920.

    Google Scholar 

  25. Pederson OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pederson C for the Danish Investigations of Arrhythmia and Morality ON Dofetilide Study Group. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) substudy. Circulation 2001;104;292–296.

    Google Scholar 

  26. Connolly SJ, Schenell DJ, Page RL, Wilkinson WE, Marcello SR, Pritchett ELC. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am J Cardiol 2001;88:974–979.

    Google Scholar 

  27. Page RL. A-STAR and A-COMET trials (abstract). Europace 2002;3:A-2.

    Google Scholar 

  28. Camm AJ, Karam R, Pratt C. The azimilide postinfarct survival evaluation (ALIVE) trial. Am J Cardiol 1998;81(6A):35D–39D.

    Google Scholar 

  29. Sun W, Sarma JSM, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart. Comparison with amiodarone. Circulation 1999;100:2276–2281.

    Google Scholar 

  30. Touboul P, Brugada J, Capucci A, Crijns H, Edvardsson N, Hohnloser S, Radzik D, on behalf of the DAFNE Investigators. Dronedarone for the prevention of recurrent atrial fibrillation after cardioversion. Results of a randomized placebo-controlled, double—blind, multicenter study (abstract). PACE 2002;24:574.

    Google Scholar 

  31. Naccarelli GV, Wolbrette DL, Dell'Orfano JT, Patel HM, Luck JC. A decade of clinical trial developments in post-myocardial infarction, congestive heart failure and sustained ventricular tachyarrhythmia patients: From CAST to AVID and beyond. J Cardiovasc Electrophysiol 1998;9:864–889.

    Google Scholar 

  32. Pritchett ELC, Wilkinson WE, Clair WK, et al. Comparison of mortality in patients treated with propafenone to those treated with a variety of antiarrhythmic drugs for supraventricular arrhythmias. AmJ Cardiol 1993;72:108–110.

    Google Scholar 

  33. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman PL, Greene HL, Huther ML, Richardson DW and the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781–788.

    Google Scholar 

  34. Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;1:1142–1147.

    Google Scholar 

  35. Julian DG, Camm AJ, Franglin G, Janse MJ, Munoz A, Schwartz PJ, Simon P for the European Myocardial Infarct Amiodarone Trial Investigators. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667–674.

    Google Scholar 

  36. Cairns, JA, Connolly SJ, Roberts R, Gent M for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators: Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675–682.

    Google Scholar 

  37. Kober L, Bloch-Thomsen PE, Moller M, et al. on behalf of the Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Study Group. Effect of dofetilide in patients with recent myocardial infarction and left ventricular dysfunction: Results of the DIAMOND-MI study. Lancet 2000;356:2052–2058.

    Google Scholar 

  38. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992;20:527–532.

    Google Scholar 

  39. Doval HC, Nul DR, Grancelli HO, et al. for Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomized Trial of Low-Dose Amiodarone in Severe Congestive Heart Failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994;344:493–498.

    Google Scholar 

  40. Singh SN, Fletcher RD, Fisher SG, et al. for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure (CHF-STAT): Amiodarone in Patients with Congestive Heart Failure and Asymptomatic Ventricular Arrhythmia (CHF-STAT). N Engl J Med 1995;333:77–82.

    Google Scholar 

  41. Cleland JGF, Thackray S, Goodge L, Kaye G, Cooklin M. Outcome studies with device therapy in patients with heart failure. J Cardiovasc Electrophysiol 2002;13:S73–S91.

    Google Scholar 

  42. Garg R, Gorlin R, Smith T, Yusuf S, for the Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–533.

    Google Scholar 

  43. Packer M, Bristow MR, Cohn JN, et al. for the U.S. Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349–1355.

    Google Scholar 

  44. CIBIS-II Investigated and Committees. The cardiac insuf-ficiency bisoprolol study II (CIBIS II): A randomized trial. Lancet 1999;353:9–13.

    Google Scholar 

  45. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001–2007.

    Google Scholar 

  46. Roy D for the AF-CHF Trial Investigators. The Atrial Fibrillation and Congestive Heart Failure TriaL (abstract). Europace 2002;3:A-11.

    Google Scholar 

  47. Hohnloser SH, Kuck KH, Lilienthal J for the PIAF Investigators. Rhythm or rate control in atrial ibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomized trial. Lancet 2000;356:1789–1794.

    Google Scholar 

  48. The Atrial Fibrillation Follow-Up Investigations of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825–1833.

    Google Scholar 

  49. Van Gelder IC, Hagens VE, Bosker HA, et al. for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834–1840.

    Google Scholar 

  50. Pederson OD, Bagger H, Kober L, Torp-Pedersen C. Trandolopril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376–380.

    Google Scholar 

  51. Madrid AH, Bueno MG, Rebollo JMG, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study. Circulation 2002;106:331–336.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology and the Pennsylvania State Cardiovascular Center, Penn State University College of Medicine, The Milton S. Hershey Medical Center, Hershey, PA, USA

    Gerald V. Naccarelli, Deborah L. Wolbrette, Luna Bhatta, Mazhar Khan, John Hynes, Soraya Samii & Jerry Luck

Authors
  1. Gerald V. Naccarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deborah L. Wolbrette
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luna Bhatta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mazhar Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John Hynes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Soraya Samii
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jerry Luck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerald V. Naccarelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Naccarelli, G.V., Wolbrette, D.L., Bhatta, L. et al. A Review of Clinical Trials Assessing the Efficacy and Safety of Newer Antiarrhythmic Drugs in Atrial Fibrillation. J Interv Card Electrophysiol 9, 215–222 (2003). https://doi.org/10.1023/A:1026240625182

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026240625182

Search

Navigation